Circulating tumor DNA methylation in colorectal cancer: a meta-analysis
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Circulating tumor DNA (ctDNA) methylation shows high accuracy for colorectal cancer (CRC) screening. Combining ctDNA methylation with carcinoembryonic antigen (CEA) further improves diagnostic performance for CRC.
Area Of Science
- Oncology
- Molecular Diagnostics
- Biomarker Discovery
Background
- Colorectal cancer (CRC) remains a significant global health challenge.
- Early detection is crucial for improving patient outcomes and survival rates.
- Circulating tumor DNA (ctDNA) methylation is emerging as a promising biomarker for cancer detection.
Purpose Of The Study
- To systematically evaluate the diagnostic accuracy of ctDNA methylation for colorectal cancer (CRC).
- To assess the performance of ctDNA methylation alone and in combination with other biomarkers.
- To identify factors influencing the diagnostic utility of ctDNA methylation assays.
Main Methods
- A comprehensive meta-analysis of published studies was conducted.
- Data from 147 articles, including 15,133 CRC patients, were synthesized.
- Pooled sensitivity, specificity, diagnostic odds ratio (DOR), and AUC were calculated.
Main Results
- ctDNA methylation demonstrated a pooled sensitivity of 0.655, specificity of 0.902, and AUC of 0.8851.
- Combining ctDNA methylation with carcinoembryonic antigen (CEA) improved AUC to 0.9269.
- Multi-gene panels and digital PCR assays showed superior diagnostic value.
Conclusions
- ctDNA methylation exhibits significant diagnostic accuracy for early CRC detection and screening.
- Combination with CEA enhances diagnostic performance, suggesting clinical utility.
- Further research is needed to address remaining questions before widespread clinical application.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.